Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators

Add time:07/13/2019    Source:sciencedirect.com

A series of N-thiazole substituted arylacetamides were designed on the basis of metabolic mechanism of the aminothiazole fragment as glucokinase (GK) activators for the treatment of type 2 diabetes. Instead of introducing a substituent to block the metabolic sensitive C-5 position on the thiazole core directly, a wide variety of C-4 or both C-4 and C-5 substitutions were explored. Compound R-9k bearing an iso-propyl group as the C-4 substituent was found possessing the highest GK activation potency with an EC50 of 0.026 μM. This compound significantly increased both glucose uptake and glycogen synthesis in rat primary cultured hepatocytes. Moreover, single oral administration of compound R-9k exerted significant reduction of blood glucose levels in both ICR and ob/ob mice. These promising results indicated that compound R-9k is a potent orally active GK activator, and is warranted for further investigation as a new anti-diabetic treatment.

We also recommend Trading Suppliers and Manufacturers of 1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-amine (cas 478832-10-9). Pls Click Website Link as below: cas 478832-10-9 suppliers

Prev:Bis-[2[(tetrahydro-2H-pyran-2-yl)thio]phenyl]diazine: A new colorimetric reagent for mercury
Next:Performance of microaeration hydrolytic acidification process in the pretreatment of 2-butenal manufacture wastewater)